GlassScriptPhysician profile
Wilbert Roy Warren
NPI 1548228489
$1,591.40
in general payments reported to CMS, 2019-2025
20 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.31 · 2022: $240 · 2023: $418 · 2024: $502 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.37 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $238.28 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $187.99 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $137.38 | 2023-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $107.94 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $103.52 | 2023-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $102.42 | 2022-2024 | |
| Shield Therapeutics INC | $67.85 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.79 | 2023-2024 | Synjardy, Jardiance |
| Eisai INC. | $42.80 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.88 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $40.48 | 2024-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $36.36 | 2023-2024 | Breztri, Airsupra |
| Astellas Pharma US INC | $22.31 | 2022 | |
| Sanofi Pasteur INC. | $20.66 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.01 | 2023 | Quviviq |
| Ucb, INC. | $15.80 | 2023 | Briviact |
| Amgen INC. | $15.59 | 2025 | Evenity |
| Phathom Pharmaceuticals, INC. | $13.58 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $13.39 | 2023 | Livalo, Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilbert Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.